Startup Claims Injectable Drug Combination Rejuvenates Blood, but Experts Raise Skepticism

Generation Lab's '1-Generation' treatment promises to reverse aging markers, with CEO and founder among early recipients. Critics question transparency and trial design.

edit

By LineZotpaper

Published28 August 2026

Read Time3 min

A startup called Generation Lab is promoting an injectable combination of two existing drugs it claims can block the systemic spread of aging in the bloodstream and restore youth to multiple tissues. The company, founded by scientist Irina Conboy, has already begun administering the treatment to a small group including its CEO and founder, who report benefits such as improved vision, stamina, and hand grip. However, the claims are met with widespread skepticism due to the company's refusal to disclose the drug names, its plan for pay-to-play clinical trials, and its association with a doctor who previously promoted treatments deemed fraudulent by the FDA.

Generation Lab, a longevity-focused startup, has announced a new rejuvenation treatment called 1-Generation, an injectable combination of two existing drugs. In a marketing pitch to select journalists, CEO Alina Su claimed the treatment "blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues." The company says it is offering access to a "private cohort" of influential individuals, with a long waitlist including celebrities.

The scientific basis for the treatment stems from the work of founder Irina Conboy, a researcher at the University of California, Berkeley, who has studied parabiosis—the surgical joining of circulatory systems between old and young animals. This procedure has been shown to reverse some signs of aging in older animals, but is not feasible in humans. Conboy says she has identified a drug combination that mimics these effects without blood exchange.

Conboy, Su, and several other insiders have been taking the drugs for two months and report subjective improvements. A spreadsheet shared with MIT Technology Review listed benefits including improved vision, longer exercise sessions, better erections, and increased bowel movements. The company plans to launch a larger study of 100 or more subjects, but participants will be required to pay for enrollment, a practice often criticized as a sales channel rather than rigorous science.

Concerns have been raised about the trial's leadership by Dr. Matt Cook, founder of BioReset Medical clinics, who was previously reported to have recommended COVID-19 treatments labeled as fraudulent by the FDA, including inhaling amniotic fluid. Generation Lab has not disclosed the identities of the two drugs in 1-Generation, making independent verification impossible.

Proponents argue that the approach is grounded in established parabiosis research and could lead to a viable antiaging therapy. Critics counter that without transparency, peer review, or standard clinical trials, the claims are premature and potentially misleading. The longevity field has struggled with unproven treatments and commercialization of hope.

Analysis

Why This Matters

If valid, a drug that reverses aging biomarkers could transform healthcare and extend healthy lifespan globally.
The pay-to-play trial model raises ethical questions about evidence generation when profit motives conflict with scientific rigor.
This case highlights the persistent challenge of separating credible longevity research from marketing hype in a lucrative, high-demand market.

Background

Parabiosis experiments date back to the 19th century, but gained modern attention in the 2000s when labs including Irina Conboy's showed that blood from young mice could rejuvenate tissues in old mice. This sparked a race to identify factors in young blood that confer benefits. Several companies, such as Alkahest and Ambrosia, attempted to commercialize young plasma transfusions, but results in humans were mixed and regulatory hurdles high. Generation Lab's approach uses existing drugs, potentially easing regulatory paths if efficacy is shown. However, the company's secrecy and marketing tactics echo earlier controversies in the antiaging industry, such as unproven supplements and stem cell clinics.

Key Perspectives

[Longevity enthusiasts and early adopters]: They are excited by the prospect of an accessible drug that mimics parabiosis benefits. Anecdotal reports from insiders add to the appeal, and many in the antiaging community may be willing to pay for access. [Scientists and medical ethicists]: They demand rigorous, transparent, placebo-controlled trials. Without disclosure of the drug combination, independent replication is impossible. Pay-to-play trials introduce bias and could endanger participants. [Critics/Skeptics]: They point to the involvement of Dr. Matt Cook, whose history of promoting unapproved treatments is a red flag. The lack of published data and the marketing to influential figures suggests hype over substance. Previous antiaging claims have repeatedly failed to translate into effective therapies.

What to Watch

Whether Generation Lab discloses the drug names in the future, either to regulators or in a scientific publication.
The design and results of the planned 100-person pay-to-play study, including any adverse events or independent oversight.
Regulatory responses from the FDA or FTC if the marketing crosses into unsubstantiated health claims.

Sources

A startup claims it’s found a drug to make your blood young — MIT Technology Review